01 September 2021 | News
Both companies will provide healthcare professionals with information on the drug
Image credit: shutterstock
Eli Lilly Japan and Daiichi Sankyo Company have concluded an agreement on commercialisation collaboration in Japan for the 5-HT1F receptor agonist lasmiditan succinate, for which Eli Lilly Japan has submitted a new drug application for the treatment of migraines.
Under the terms of the agreement, Eli Lilly Japan will hold authorisation for marketing lasmiditan succinate, similar to the humanized anti-CGRP monoclonal antibody Emgality (generic name: galcanezumab (genetic recombination)) to which a sales agreement has already been concluded between the two companies, and Daiichi Sankyo will take charge of its distribution and sales after marketing approval. Both companies will provide healthcare professionals with information on the drug.
Both companies will provide healthcare professionals with information on the drug. Through this commercialisation collaboration with Daiichi Sankyo, which has a solid operating foundation in Japan based on its established position and global network in the fields of central nervous system diseases and pain management, Eli Lilly Japan will strengthen its system for providing healthcare professionals with proper information through both Emgality and lasmiditan succinate after obtaining marketing approval.
Eli Lilly Japan and Daiichi Sankyo will work more closely together than ever before through this commercialisation collaboration for galcanezumab and lasmiditan succinate to advance the medical treatment of migraine in Japan and contribute to giving people with migraine opportunities to live moments that matter and days.